×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RNXT – renovorx, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RNXT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/16
08:40 am
rnxt
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community [Yahoo! Finance]
High
Report
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community [Yahoo! Finance]
4/16
08:30 am
rnxt
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
Medium
Report
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
4/4
08:30 am
rnxt
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
Medium
Report
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
4/4
08:14 am
rnxt
RenovoRx, Inc. (NASDAQ: RNXT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
RenovoRx, Inc. (NASDAQ: RNXT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/1
08:30 am
rnxt
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Medium
Report
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
3/28
08:00 am
rnxt
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
Low
Report
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
3/27
08:15 am
rnxt
RenovoRx, Inc. (NASDAQ: RNXT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Neutral
Report
RenovoRx, Inc. (NASDAQ: RNXT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
3/26
08:53 am
rnxt
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting [Yahoo! Finance]
Medium
Report
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
06:10 am
rnxt
Form 4 RenovoRx, Inc. For: Apr 15 Filed by: Agah Ramtin
Medium
Report
Form 4 RenovoRx, Inc. For: Apr 15 Filed by: Agah Ramtin
4/16
05:18 pm
rnxt
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Gentry Leesa
Low
Report
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Gentry Leesa
4/16
05:18 pm
rnxt
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Agah Ramtin
Low
Report
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Agah Ramtin
4/16
05:18 pm
rnxt
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Kocak Ron
Low
Report
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Kocak Ron
4/16
05:18 pm
rnxt
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Bagai Shaun
Low
Report
Form 4 RenovoRx, Inc. For: Apr 14 Filed by: Bagai Shaun
4/16
06:08 am
rnxt
Form 4 RenovoRx, Inc. For: Apr 15 Filed by: Bagai Shaun
High
Report
Form 4 RenovoRx, Inc. For: Apr 15 Filed by: Bagai Shaun
4/14
06:30 am
rnxt
Form 4 RenovoRx, Inc. For: Apr 11 Filed by: Agah Ramtin
Medium
Report
Form 4 RenovoRx, Inc. For: Apr 11 Filed by: Agah Ramtin
4/10
07:02 pm
rnxt
Form 4 RenovoRx, Inc. For: Apr 08 Filed by: Kocak Ron
Medium
Report
Form 4 RenovoRx, Inc. For: Apr 08 Filed by: Kocak Ron
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: